Abstract 123P
Background
A novel fusion gene of EML4-ALK and ROS 1 has been identified in a subset of non-small-cell lung cancers (NSCLCs). Patients with the ALK-EML4 and ROS1 fusion gene demonstrate unique clinicopathological characteristics and treatment with targeted therapy led to improved survivals.
Methods
Data of advanced NSCLC patients diagnosed between 2016 and 2022 with ALK and ROS1 positivity were analyzed. Detection of ALK was done by IHC or fluorescent in situ hybridization (FISH) and ROS1 was done by FISH.
Results
A total of 776 advanced NSCLC patients between 2016 and 2022 were tested for ALK of which 63(8.1%) were positive. The median age at presentation was 50 years (range,19-80 years). Of 63 patients, 34(54%) were males and 29(46%) were females. Cough (83%) was the most common symptom at presentation followed by dyspnea (73%), anorexia (59%) weight loss (59%) and chest pain (43%). The median duration of symptoms was 3 months. 44(86%) patients were never smokers and 9(14%) patients had history of smoking or tobacco usage. The most common site of metastases was opposite lung(59%), bone(50%) followed by pleural effusion(41%). Brain metastasis were seen in 13(21%) patients. Detection of ALK positivity was done by IHC and FISH in 45(72%) and 18(28%) patients respectively. Of 63 patients, 52 patients received atleast 4 months of treatment and were assessed for survival. First-line therapy was crizotinib, chemotherapy followed by maintenance crizotinib, ceritinib, alectinib in 40(77%), 4(7.7%), 6(11.5%) and 2(3.8%) patients. The median PFS was 16 months (range, 4-52). At a median follow up of 14 months, the 1-year progression free and overall survival was 71% and 75%. The 2 year and 3 year OS were 54% and 30% . Out of 322 patients tested for ROS1, 9(2.8%) were positive for ROS1 translocation and received first-line therapy with Crizotinib. The one year PFS and OS were 75% and 89%.
Conclusions
ALK and ROS1 positivity was seen in 8.1% and 2.8% of advanced NSCLC patients. Majority of patients were never smokers. Opposite lung and bone were the most common site of metastases. 3/4th of the patients had one-year survival rate and the survival rates in the real world are better than reported in the randomized studies. Crizotinib is well tolerated in majority of patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Nizam's Institute of Medical Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
72P - Role of pyruvate carboxykinase 2 upregulation in group 3 medulloblastoma: Implications for metabolic reprogramming and therapeutic strategies
Presenter: MEDHA GAYATHRI PAI
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis
Presenter: Lysanne Desharnais
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Possible significance of the proline at position 325 in the recognition of the MX35 epitope of the NaPi2b transporter by monoclonal antibodies
Presenter: Leisan Bulatova
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression
Presenter: Simon Milette
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response
Presenter: Alba de Juan
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Single-cell spatial landscape of NSCLC reveals subtype specific immune features
Presenter: Mark Sorin
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: XIAOHE ZHOU
Session: Cocktail & Poster Display session
Resources:
Abstract